All In Biotech

Drug Trial Radar · NCT01887600

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

594

Actual

Start

Sep 3, 2013

Primary completion

Nov 1, 2017

Study completion Nov 1, 2017

Sponsor

Lead sponsor
Astellas Pharma Europe B.V.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Kyntra Bio
First posted
Jun 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if Roxadustat is both effective and safe as a treatment for anemia in patients with chronic kidney disease.

Conditions

  • Anemia in Chronic Kidney Disease in Non-dialysis Patients

Interventions

  • RoxadustatDrug

    Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.

  • PlaceboDrug

    Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb ResponseTime frame: Baseline to week 24
  2. Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue TherapyTime frame: Baseline and weeks 28 to 52

Locations

138 sites in 22 countries. Site status is shown where the registry gives one.

  • Site BY37503

    Brest, Belarus

  • Site BY37501

    Grodno, Belarus

  • Site BY37504

    Homyel, Belarus

  • Site BY37506

    Minsk, Belarus

  • Site BY37507

    Minsk, Belarus

  • Site BY37505

    Minsk, Belarus

  • Site BY37502

    Vitebsk, Belarus

  • Site BE32002

    Antwerp, Belgium

  • Site BE32012

    Baudour, Belgium

  • Site BE32017

    Bonheiden, Belgium

  • Site BE32014

    Ieper, Belgium

  • Site BE32013

    Liège, Belgium

  • Site BE32004

    Brussels, Flemish Brabant, Belgium

  • Site BG35923

    Pazardzhik, Bulgaria

  • Site BG35906

    Sofia, Bulgaria

  • Site BG35908

    Sofia, Bulgaria

  • Site BG35910

    Sofia, Bulgaria

  • Site BG35907

    Stara Zagora, Bulgaria

  • Site BG35916

    Varna, Bulgaria

  • Site BG35903

    Veliko Tarnovo, Bulgaria

  • Site CO57007

    Barranquilla, Colombia

  • Site CO57008

    Barranquilla, Colombia

  • Site CO57002

    Pereira, Colombia

  • Site DO17101

    La Fe Santo Domingo, Dominican Republic

  • Site DO17102

    Santiago de los Caballeros, Dominican Republic

  • Site DO17104

    Santo Domingo, Dominican Republic

  • Site DO17103

    Santo Domingo, Dominican Republic

  • Site EE37201

    Tallinn, Estonia

  • Site GE99503

    Tbilisi, Georgia

  • Site GE99504

    Tbilisi, Georgia

  • Site GE99502

    Tbilisi, Georgia

  • Site GR30003

    Heraklion, Greece

  • Site GR30002

    Pátrai, Greece

  • Site GR30001

    Thessaloniki, Greece

  • Site GT50209

    Chiquimula, Guatemala

  • Site GT50205

    Guatemala City, Guatemala

  • Site GT50206

    Guatemala City, Guatemala

  • Site GT50203

    Guatemala City, Guatemala

  • Site GT50202

    Guatemala City, Guatemala

  • Site GT50208

    Guatemala City, Guatemala

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.